Trends in DRM prevalence
The initial samples for 2,107 patients collected over 5 years were assessed. The overall prevalence of DRMs, including all DRM types (low-level, intermediate, and high-level mutations), declined from 39.4% before 2018 to 31.6% in 2022 (Figure 3). The prevalence of high-level resistance mutations, which are more clinically significant, also declined from 16.7% to 7.7% between 2018 and 2022. The DRM trends in NRTIs and INSTIs decreased from 14.5% to 6.4% and 8.0% to 1.7%, respectively, whereas NNRTIs showed a lateral trend from 27.7% to 26.3%. The DRM trends in PIs declined steadily from 39.4% to 31.6%.